Johnson & Johnson (JNJ) Stock Forecast & Price Target

$153.52 -0.14 (-0.09%)

As of 11:06 AM Eastern

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
11

Buy
9

Based on 20 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 11 have given a hold rating, 7 have given a buy rating, and 2 have given a strong buy rating for JNJ.

Consensus Price Target

$170.88
11.31% Upside

According to the 20 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $170.88. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 11.31% from the current price of $153.52.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

JNJ Analyst Ratings Over Time

Type	Current Forecast 5/21/24 to 5/21/25	1 Month Ago 4/21/24 to 4/21/25	3 Months Ago 2/21/24 to 2/20/25	1 Year Ago 5/22/23 to 5/21/24
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	11 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$170.88	$171.82	$170.67	$175.86
Forecasted Upside	11.31% Upside	9.44% Upside	6.92% Upside	16.27% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	S&P 500
Consensus Rating Score	2.55	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.27% Upside	4,843.18% Upside	13.03% Upside
News Sentiment Rating	Positive News See Recent JNJ News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/13/2025	Leerink Partnrs 1 of 5 stars	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	Leerink Partners 1 of 5 stars	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00	-0.57%
4/24/2025	Benchmark 2 of 5 stars	T. Brooks Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/17/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $165.00	+4.44%
4/16/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform
4/16/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00	+16.93%
4/16/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$164.00 ➝ $169.00	+9.17%
4/14/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$165.00 ➝ $162.00	+5.42%
4/10/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$171.00 ➝ $159.00	+6.70%
4/9/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$157.00 ➝ $172.00	+15.25%
Get the Latest News and Ratings for JNJ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.
4/2/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
1/24/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/23/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$170.00 ➝ $155.00	+5.58%
1/23/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $152.00	+4.55%
12/11/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$185.00 ➝ $175.00	+19.18%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$190.00	+25.12%
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $215.00	+30.70%
7/23/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$160.00 ➝ $150.00	-2.75%
7/18/2024	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$195.00 ➝ $185.00	+18.03%
7/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$195.00 ➝ $185.00	+18.38%
4/18/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$169.00 ➝ $170.00	+17.43%
12/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$167.00 ➝ $180.00	+16.39%
8/4/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$167.00 ➝ $170.00	-0.42%
7/21/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$175.00 ➝ $180.00	+5.75%
7/21/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$170.00 ➝ $175.00	+3.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:53 AM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 19, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

The company recently reported earnings per share of $2.77, exceeding expectations, which indicates strong financial performance and potential for growth.
Johnson & Johnson has a robust return on equity of 34.24%, suggesting effective management and profitability, which can be attractive to investors looking for solid returns.
The current stock price is around $165, reflecting a stable investment opportunity in the healthcare sector.
With a recent quarterly dividend increase to $1.30 per share, the company demonstrates a commitment to returning value to shareholders, which can enhance investor confidence.
Analysts have a consensus rating of "Moderate Buy" with an average price target of $170.88, indicating positive market sentiment and potential for stock appreciation.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

Recent insider selling, including significant transactions by executives, may raise concerns about the company's future performance and insider confidence.
Some analysts have downgraded the stock's rating, which could indicate potential challenges ahead and affect investor sentiment negatively.
The company's payout ratio is 57.84%, which, while manageable, suggests that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
Market volatility and economic uncertainties could impact the healthcare sector, affecting Johnson & Johnson's performance and stock price.
Institutional investors hold a significant portion of the stock (69.55%), which can lead to increased volatility if large investors decide to sell their positions.

JNJ Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $170.88, with a high forecast of $215.00 and a low forecast of $150.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 11 hold ratings, 7 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JNJ shares.
: According to analysts, Johnson & Johnson's stock has a predicted upside of 11.31% based on their 12-month stock forecasts.
: Over the previous 90 days, Johnson & Johnson's stock had 2 upgrades and 2 downgrades by analysts.
: Johnson & Johnson has been rated by research analysts at Bank of America, Barclays, Benchmark, Guggenheim, Leerink Partners, Leerink Partnrs, Morgan Stanley, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, and The Goldman Sachs Group in the past 90 days.
: Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating score for Johnson & Johnson is 2.55 while the average consensus rating score for "medical" companies is 2.81. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:JNJ) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Stock Forecast & Price Target